- For imminent preeclampsia, the combination of mean arterial pressure (MAP), placental growth factor (PLGF), and soluble fms-like tyrosine linase-1s (sFLT) may represent a third-trimester test.
Why this matters
- Screening tests for imminent preeclampsia would help in management and timing of delivery and reducing maternal complications.
- 2.1% developed preeclampsia.
- The combination of history, MAP, PLGF, and sFLT (triple test) was superior to PLGF alone or the sFLT/PLGF ratio.
- The positive predictive values (PPVs) were:
- 17.9 (cutoff 10; 95% CI, 13.3-23.2) in predicting delivery ≤2 weeks, and
- 32.9 (cutoff 10, 95% CI, 27.2-39.1) in predicting delivery ≤4 weeks.
- The negative predictive value (NPV) was similar for the 3 tests.
- Prospective observational study.
- Women undergoing routine visit at 35 weeks 0 days to 36 weeks 6 days enrolled (n=15,247).
- Serum PLGF and sFLT measured.
- Detection rate, PPV, and NPV calculated using various combinations of medical history, physical findings, and serum markers.
- Outcome measures included delivery with preeclampsia ≤2 and ≤4 weeks after assessment.
- Funding: The Fetal Medicine Foundation.
- Heterogeneous group.
- These serum marker tests are not available for routine use.
- Model needs validation.